This study is looking at how a single dose of psilocybin (25mg) affects feelings of loneliness and social connection in adults aged 21 to 65. You might be able to join if you are medically healthy, feel very lonely (based on a specific scale), or have unresolved grief. Researchers want to see if psilocybin can reduce how your brain reacts to negative social situations, and if this leads to better social connectedness. You would either receive psilocybin or a placebo (an inactive capsule). The study is currently unclear on its recruitment status.

Study design

This is a randomized, double-blind, placebo-controlled study, meaning participants are randomly assigned to receive either psilocybin or a placebo, and neither you nor the researchers will know which you receive. It plans to enroll 51 participants.

What's involved

You would have assessments at baseline (Day -1), Day +7, and Day +30. You would also have fMRI brain scans at Day -2 and Day +7.

Compensation

Not stated in the trial record.

Follow-up

Your loneliness and social connectedness will be measured up to Day +30 after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.